SEC Form 4 · accession 0001104659-18-072394
Aridis Pharmaceuticals, Inc. · ARDS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Fred Kurland
Officer — Chief Financial Officer
Period of report
Dec 5, 2018
Accepted (ET)
Dec 11, 2018 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001614067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $8.50 | Dec 5, 2018 | A | 17,000 | A | — | Dec 5, 2028 | Common Stock | 17,000 | 40,024 | D |
Explanation of responses
- F1The shares underlying this stock option vest as follows: in equal annual installments over the 48 months following the date of grant.